Pfizer, J&J to discontinue Alzheimer’s drug clinical studies

Hannah Blake


Following our recent news that Pfizer and J&amp,J had announced their Alzheimer’s drug failed to show effectiveness in a late-stage trial, the pharmaceutical companies have decided to discontinue all studies of the Alzheimer’s drug, bapineuzumab, in its intravenous (IV) form.

The companies have announced that the drug did not meet co-primary clinical endpoints and that there was no change in cognitive and functional performance compared to placebo, in the Janssen Alzheimer Immunotherapy R&amp,D LLC-led Phase 3 trial, in patients with mild to moderate Alzheimer’s disease who do not carry the ApoE4 genotype.

“We are obviously very disappointed in the outcomes of this trial. We are also saddened by the lost opportunity to provide a meaningful advance for patients afflicted with mild-to-moderate Alzheimer’s disease and their caregivers.”

Steven Romano, head of Pfizer’s Medicines Development Group, said in a statement.

Hope for patients with Alzheimer’s disease has not faded just yet, as Eli Lilly &amp, Co is currently developing a similar drug, called solanezumab. Late stage results will be released later on this year, however, this drug is still considered a long-shot to succeed.


Related news:

Pfizer, J&amp,J scrap Alzheimer’s studies as drug fails (Reuters)

Reference links:


Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.